BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lazertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lazertinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05463224-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05463224)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Laze
 rtinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patient
 s\nEstimated primary completion: 1 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05463224
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02609776-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lazertinib: Phase 1 readout est. (NCT02609776)
DESCRIPTION:Lazertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Amivantamab\, a Human Bispecific EGFR and cMet Antibody\, in Particip
 ants With Advanced Non-Small Cell Lung Cancer\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lazertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02609776
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077463-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Lazertinib: Phase 1 readout est. (NCT04077463)
DESCRIPTION:Lazertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Lazertinib as Monotherapy or in Combination With Amivantamab in Par
 ticipants With Advanced Non-small Cell Lung Cancer\nEstimated primary comp
 letion: 12 February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lazertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04077463
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enha
 nced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth
  Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated
  First-line With Amivantamab Plus Lazertinib\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lazert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06120140
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Participants With Advanced or Metastatic Solid Tumor
 s Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell
  Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Lazertinib: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in P
 articipants With Resectable EGFR-Mutated NSCLC\nEstimated primary completi
 on: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/laz
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07586202
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268210-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06268210)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mut
 ated Resectable Non-small Cell Lung Cancer\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lazertinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0626
 8210
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05541822-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05541822)
DESCRIPTION:Lazertinib\, phase 2.\nStudy: To Evaluate the Efficacy\, Safety
 \, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Adv
 anced Solid Tumors Harboring c-MET Dysregulation\nEstimated primary comple
 tion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lazertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05541822
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Comb
 ination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fac
 tor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106802-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06106802)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Laze
 rtinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified
  Who Progressed After Lazertinib Treatment\nEstimated primary completion: 
 30 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/la
 zertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06106802
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507188-2019@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Lazertinib: Phase 2 readout est. (NCT07507188)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Coll
 aborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and
  Amivantamab Plus Chemotherapy in Patients With EGFR-mutant\, Locally Adva
 nced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)\nEs
 timated primary completion: 31 January 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07507188
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
